Successes and Limitations of Targeted Cancer Therapy in Breast Cancer

2014 ◽  
pp. 15-35 ◽  
Author(s):  
Giuseppe Curigliano ◽  
Carmen Criscitiello
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Targeted Cancer Therapy

3D bioprinting of engineered breast cancer constructs for personalized and targeted cancer therapy

2021 ◽  
Vol 333 ◽  
pp. 91-106
Author(s):  
Majid Sharifi ◽  
Qian Bai ◽  
Mohammad Mahdi Nejadi Babadaei ◽  
Farhan Chowdhury ◽  
Mahbub Hassan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Targeted Cancer Therapy ◽  
3D Bioprinting

scholarly journals Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy

2020 ◽  
Vol 11 (11) ◽  
Author(s):  
Yidi Guan ◽  
Shilong Jiang ◽  
Wenling Ye ◽  
Xingcong Ren ◽  
Xinluan Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Signaling Pathways ◽  
Breast Cancer Cells ◽  
Mtor Inhibitor ◽  
Mtor Inhibitors ◽  
Targeted Cancer Therapy ◽  
Synergistic Cytotoxicity ◽  
Wide Range

Abstract Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors rapalogs are promising anticancer agents in clinical trials; however, rapalogs resistance remains an unresolved clinical challenge. Therefore, understanding the mechanisms by which cells become resistant to rapalogs may guide the development of successful mTOR-targeted cancer therapy. In this study, we found that eEF-2K, which is overexpressed in cancer cells and is required for survival of stressed cells, was involved in the negative-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors. Therefore, disruption of eEF-2K simultaneously abrogates the two critical resistance signaling pathways, sensitizing breast cancer cells to rapalogs. Importantly, we identified mitoxantrone, an admitted anticancer drug for a wide range of tumors, as a potential inhibitor of eEF-2K via a structure-based virtual screening strategy. We further demonstrated that mitoxantrone binds to eEF-2K and inhibits its activity, and the combination treatment of mitoxantrone and mTOR inhibitor resulted in significant synergistic cytotoxicity in breast cancer. In conclusion, we report that eEF-2K contributes to the activation of resistance signaling pathways of mTOR inhibitor, suggesting a novel strategy to enhance mTOR-targeted cancer therapy through combining mitoxantrone, an eEF-2K inhibitor.

scholarly journals Monocyte cell membrane-derived nanoghosts for targeted cancer therapy

Nanoscale ◽  
2016 ◽  
Vol 8 (13) ◽  
pp. 6981-6985 ◽  
Author(s):  
S. Krishnamurthy ◽  
M. K. Gnanasammandhan ◽  
C. Xie ◽  
K. Huang ◽  
M. Y. Cui ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Cell Membrane ◽  
Cellular Uptake ◽  
Breast Cancer Cell Lines ◽  
Core Shell ◽  
Targeted Cancer Therapy ◽  
Monocyte Cell ◽  
Coated Nanoparticle ◽  
Mcf 7

Core–shell type ‘nanoghosts’ were synthesized with a biodegradable PLGA core and a monocyte cell membrane-derived shell. The ∼200 nm doxorubicin-loaded nanoghosts showed greater cellular uptake and cytotoxicity compared to non-coated nanoparticle controls in metastatic MCF-7 breast cancer cell lines.

(TA)MUC1 as a potential new target for breast cancer therapy

2020 ◽  
Author(s):  
AS Heimes ◽  
P Fries ◽  
N Stergiou ◽  
R Attariya ◽  
A Hasenburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Breast Cancer Therapy

Off-label drug use in breast cancer therapy

Oncoreview ◽  
2017 ◽  
Vol 7 (2) ◽  
pp. 83-87
Author(s):  
Tomasz Jankowski ◽  
Monika Urbaniak
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Drug Use ◽  
Breast Cancer Therapy ◽  
Off Label
Sign in / Sign up

Export Citation Format

Share Document